Targeting DNA repair and the cell cycle in glioblastoma
Journal of Neuro-Oncology, ISSN: 0167-594X, Vol: 107, Issue: 3, Page: 463-477
2012
- 30Citations
- 63Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations30
- Citation Indexes30
- 30
- CrossRef19
- Captures63
- Readers63
- 63
Review Description
Glioblastoma is a disease with poor outcomes despite standard therapy. Specific targeting of the DNA damage response is a strategy that is becoming increasingly employed in oncology and has intriguing potential for improving outcomes in glioblastoma. DNA damage targeting has implications for improving current therapy as well as the potential to leverage inherent differences in glioblastoma cells to widen the therapeutic window. © Springer Science+Business Media, LLC. 2012.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84864332587&origin=inward; http://dx.doi.org/10.1007/s11060-011-0765-4; http://www.ncbi.nlm.nih.gov/pubmed/22113697; http://link.springer.com/10.1007/s11060-011-0765-4; https://dx.doi.org/10.1007/s11060-011-0765-4; https://link.springer.com/article/10.1007/s11060-011-0765-4; http://www.springerlink.com/index/10.1007/s11060-011-0765-4; http://www.springerlink.com/index/pdf/10.1007/s11060-011-0765-4
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know